Table 1.
Biological function of lncRNAs in carcinomas.
| Biological Function | LncRNA | Target Gene/Pathway | Cancer Type | Reference |
|---|---|---|---|---|
| Promote proliferation, migration, and invasion | LINC00052 | miR-608/EGFR | Head and neck cancer | 32 |
| AC009022.1 | miR-497-5p | Colorectal cancer | 33 | |
| DLGAP1-AS1 | miR-486-5p | Hepatocellular cancer | 34 | |
| GHSROS | – | Breast cancer | 35 | |
| LINC00337 | TIMP2/DNMT1 | Non-small-cell lung cancer | 36 | |
| AK001058 | ADAMTS12 | Colorectal cancer | 37 | |
| FOXD2-AS1 | miR-185-5p | Thyroid cancer | 38 | |
| LINC00460 | – | Colorectal cancer | 39 | |
| LINC00908 | Sox-4 | Hepatocellular cancer | 40 | |
| PVT1 | Smad3/miR-140-5p | Cervical cancer | 41 | |
| RAIN | RUNX2 | Breast and thyroid cancer | 42 | |
| LINC00673 | miR-515-5p/MARK4/Hippo | Breast cancer | 43 | |
| TTN-AS1 | KLF15 | Colorectal cancer | 44 | |
| SNHG4 | ZIC5 | Prostate cancer | 45 | |
| SOX2-OT | miR-369-3p/CFL2 | Prostate cancer | 46 | |
| LINC01559 | YAP | Pancreatic cancer | 47 | |
| VCAN-AS1 | p53 | Gastric cancer | 48 | |
| Suppress proliferation and invasion | OSER1-AS1 | miR-372-3p/Rab23 | Hepatocellular cancer | 49 |
| ZEB1-AS1 | ZEB1 | Esophageal cancer | 50 | |
| NBAT-1 | PKM2 | Esophageal cancer | 51 | |
| ENST00000489676 | MiR-922 | Thyroid cancer | 52 | |
| CASC2c | ERK1/2, Wnt/β-catenin | Hepatocellular cancer | 53 | |
| GAS5 | YAP | Colorectal cancer | 54 | |
| ADAMTS9-AS2 | CDH3 | Esophageal cancer | 55 | |
| TCONS_00020456 | Smad2/PKCα | Glioblastoma | 56 | |
| Estimate prognosis and efficacy | UCA1, H19 | 5-fluorouracil | Rectal cancer | 57 |
| ADAMTS9-AS2 | FUS/MDM2 | Glioblastoma | 58 | |
| INCAC112721.1, AL356479.1, LINC00466 | hsa-miR-204 | Breast cancer | 59 | |
| GAS5, HOTAIR, H19, MALAT | – | Colorectal cancer | 60 | |
| HOXA-AS3 | HOXA3 | Non-small-cell lung cancer | 61 | |
| Act as potential biomarkers | MALAT1 | – | Breast cancer | 62 |
| HOTAIR | – | Breast cancer | 63 | |
| PURPL, NONHSAT062994 | – | Gastric cancer | 47 | |
| SNHG11 | – | Colorectal cancer | 64 | |
| SNHG12 | – | Pan-cancer | 65 |
Note: References 32–48 discuss the promotion of cancer cell proliferation and invasion, references 49–56 discuss the suppression of cancer cell proliferation and invasion, references 57–61 discuss the estimation of the prognosis, and references 62–66 discuss efficacy or potential biomarkers.